SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (1310)9/26/2005 3:00:38 AM
From: tuck  Read Replies (1) | Respond to of 1321
 
Eligard is losing traction, too, but there is some other stuff. Early and middle stage pipe, some generic business, Aczone, etc. I haven't attempted to value QLT on the assumption that Visudyne and Eligard are on their way out, the latter perhaps more slowly. At some point, it might be a value play based on what's left.

Cheers, Tuck


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News